{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:22Z","timestamp":1792068862502,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118784","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:56:22Z","timestamp":1787756182000},"page":"118784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2\/c-MET antagonists"],"prefix":"10.1016","volume":"143","author":[{"given":"Mohamed","family":"El-Naggar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rofaida","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona M.","family":"Kabeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan A.","family":"Shehadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud S.","family":"Elkotamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bmc.2026.118784_bb0005","article-title":"Global oncology: tackling disparities and promoting innovations in low-and middle-income countries","volume":"45","author":"Barragan-Carrillo","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.bmc.2026.118784_bb0010","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.bmc.2026.118784_bb0015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/cac2.12207","article-title":"Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020","volume":"41","author":"Lei","year":"2021","journal-title":"Cancer Commun"},{"issue":"5","key":"10.1016\/j.bmc.2026.118784_bb0020","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1039\/D5MD01147G","article-title":"Structure-based design of potent pyrazolo [1, 5-a] pyrimidine CDK4\/6 inhibitors: biological evaluation and computational validation","volume":"17","author":"Binjubair","year":"2026","journal-title":"RSC Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118784_bb0025","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1039\/D5MD01043H","article-title":"Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2\/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitization","volume":"17","author":"Eldehna","year":"2026","journal-title":"RSC Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118784_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cells14090673","article-title":"The distinct role of HIF-1\u03b1 and HIF-2\u03b1 in hypoxia and angiogenesis","volume":"14","author":"Bakleh","year":"2025","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bmc.2026.118784_bb0035","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1517\/14728222.2013.730522","article-title":"Tumor vasculature: the Achilles\u2019 heel of cancer?","volume":"17","author":"Johannessen","year":"2013","journal-title":"Expert Opin Ther Targets"},{"issue":"16","key":"10.1016\/j.bmc.2026.118784_bb0045","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.3390\/ijms25169101","article-title":"Unveiling the role of HGF\/c-Met signaling in non-small cell lung cancer tumor microenvironment","volume":"25","author":"Yao","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.bmc.2026.118784_bb0050","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.3390\/molecules25112666","article-title":"Research progress of small molecule VEGFR\/c-Met inhibitors as anticancer agents (2016\u2013present)","volume":"25","author":"Zhang","year":"2020","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.bmc.2026.118784_bb0055","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1039\/D6MD00022C","article-title":"Pyrazole\u2013triazole hybrids as kinase-triad inhibitors: a triple-target strategy for synergistic anticancer therapy","volume":"17","author":"Elkotamy","year":"2026","journal-title":"RSC Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118784_bb0060","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.3390\/ijms19123844","article-title":"HGF\/c-MET signaling in melanocytes and melanoma","volume":"19","author":"Czyz","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12935-018-0530-2","article-title":"Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma","volume":"18","author":"Lai","year":"2018","journal-title":"Cancer Cell Int"},{"issue":"6","key":"10.1016\/j.bmc.2026.118784_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304782","article-title":"Vorolanib, sunitinib, and axitinib: a comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects","volume":"19","author":"Bakri","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bmc.2026.118784_bb0075","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1021\/acsabm.4c01527","article-title":"Tyrosine kinase inhibitor lenvatinib based nano formulations and cutting-edge scale-up technologies in revolutionizing cancer therapy","volume":"8","author":"Shaikh","year":"2025","journal-title":"ACS Appl Bio Mater"},{"issue":"22","key":"10.1016\/j.bmc.2026.118784_bb0080","doi-asserted-by":"crossref","first-page":"15140","DOI":"10.1021\/acs.jmedchem.2c00981","article-title":"Discovery of D6808, a highly selective and potent macrocyclic c-met inhibitor for gastric cancer harboring MET gene alteration treatment","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2013.10.006","article-title":"Major partial response to crizotinib, a dual MET\/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement","volume":"83","author":"Schwab","year":"2014","journal-title":"Lung Cancer"},{"issue":"19","key":"10.1016\/j.bmc.2026.118784_bb0090","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.3390\/cancers15194708","article-title":"Savolitinib: a promising targeting agent for cancer","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bmc.2026.118784_bb0095","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non\u2013small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bmc.2026.118784_bb0100","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bmc.2026.118784_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbrc.2022.02.045","article-title":"Dual blockade of MET and VEGFR2 signaling pathways as a potential therapeutic maneuver for peritoneal carcinomatosis in scirrhous gastric cancer","volume":"600","author":"Kasai","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.bmc.2026.118784_bb0110","article-title":"Thiadiazole-derived VEGFR-2 inhibitors: from design to anticancer evaluation","volume":"107","author":"lsfouk","year":"2026","journal-title":"Chem Biol Drug Des"},{"issue":"5","key":"10.1016\/j.bmc.2026.118784_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70333","article-title":"Identification of sulfonamide-based thiazolidine-2, 4-dione derivatives as VEGFR-2 and tumor-associated hCA IX inhibitors with hypoxia-targeted anti-colorectal cancer activity","volume":"87","author":"Tawfik","year":"2026","journal-title":"Drug Dev Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s44371-024-00057-z","article-title":"A brief review on imidazole, triazine, and isatin derivatives: synthesis approaches and their applications","volume":"1","author":"Parmar","year":"2024","journal-title":"Discov Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118784_bb0125","doi-asserted-by":"crossref","first-page":"1900367","DOI":"10.1002\/ardp.201900367","article-title":"Recent advances in isatin hybrids as potential anticancer agents","volume":"353","author":"Ding","year":"2020","journal-title":"Arch Pharm"},{"issue":"6","key":"10.1016\/j.bmc.2026.118784_bb0130","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1039\/D6MD00023A","article-title":"Recent advances in the development of acridine-based hybrids with antiproliferative activity","volume":"17","author":"Gallala","year":"2026","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107626","article-title":"Unveiling the potential of isatin-grafted phenyl-1, 2, 3-triazole derivatives as dual VEGFR-2\/STAT-3 inhibitors: design, synthesis and biological assessments","volume":"151","author":"Elsebaie","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107829","article-title":"Design, synthesis, and in silico insights of novel N\u2019-(2-oxoindolin-3-ylidene) piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors","volume":"153","author":"Eldehna","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107644","article-title":"Novel imidazo [2, 1-b] thiazoles and imidazo [1, 2-a] pyridines tethered with indolinone motif as VEGFR-2 inhibitors and apoptotic inducers: design, synthesis and biological evaluations","volume":"151","author":"Elkotamy","year":"2024","journal-title":"Bioorg Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118784_bb0150","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1016\/j.bmcl.2011.04.064","article-title":"Identification and synthesis of N\u2032-(2-oxoindolin-3-ylidene) hydrazide derivatives against c-met kinase","volume":"21","author":"Liang","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118784_bb0155","article-title":"Design, synthesis, and bioactivity assessment of highly potent isatin-based small-molecules bearing 3-hydrazineyl-6-aryl-1, 2, 4-triazine moieties as potential c-MET targeting anticancer agents","volume":"176","author":"Khatir","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109608","article-title":"Synthesis of 4-chloro-N\u2032-(2-cyanoacetyl) benzohydrazide derivatives, cytotoxicity, VEGFR-2\/EGFRT790M bioassays and in silico docking\/ADMET studies","volume":"172","author":"Deghaidi","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0165","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.bioorg.2018.01.014","article-title":"Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-met","volume":"77","author":"Ibrahim","year":"2018","journal-title":"Bioorg Chem"},{"issue":"16","key":"10.1016\/j.bmc.2026.118784_bb0170","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1080\/00397911.2020.1784436","article-title":"Investigation of the reactivity of (1 H-benzo [d] imidazol-2-yl) acetonitrile and (benzo [d] thiazol-2-yl) acetonitrile as precursors for novel bis (benzo [4, 5] imidazo [1, 2-a] pyridines) and bis (benzo [4, 5] thiazolo [3, 2-a] pyridines)","volume":"50","author":"Darweesh","year":"2020","journal-title":"Synth Commun"},{"key":"10.1016\/j.bmc.2026.118784_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.137554","article-title":"Spiro-fused indoline-quinazoline hybrids as smart bombs against TNF-\u03b1-mediated inflammation","volume":"283","author":"Elkotamy","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118784_bb0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3987\/COM-14-13160","article-title":"Reactivity of 2-(1-methyl-1H-benzo [d] imidazol-2-yl)-2-nitrosoacetonitrile: a facile one-pot synthesis of Benzimidazo [1, 2-a] piperazine derivatives","volume":"91","author":"Sayed","year":"2015","journal-title":"Heterocycles"},{"key":"10.1016\/j.bmc.2026.118784_bb0185","series-title":"Drug Design and Discovery: Methods and Protocols","first-page":"157","article-title":"Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability","author":"Sylvester","year":"2011"},{"issue":"18","key":"10.1016\/j.bmc.2026.118784_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.bmc.2026.118784_bb0195","series-title":"Cancer Cell Culture: Methods and Protocols","first-page":"237","article-title":"Cell sensitivity assays: the MTT assay","author":"Van Meerloo","year":"2011"},{"issue":"13","key":"10.1016\/j.bmc.2026.118784_bb0200","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.3390\/ijms22136923","article-title":"The influence of cell cycle regulation on chemotherapy","volume":"22","author":"Sun","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.bmc.2026.118784_bb0205","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/092986707780362925","article-title":"Targeting cell cycle kinases for cancer therapy","volume":"14","author":"de C\u00e1rcer","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2026.109846","article-title":"Click chemistry synthesis of triazole-grafted quinazolinones as new multi-panel anticancer agents: mechanistic insights into apoptosis and cell cycle arrest in colorectal cancer","volume":"176","author":"Al-Sanea","year":"2026","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118784_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140462","article-title":"Development of pyrazolo [1, 5-a] pyrimidine-grafted coumarins as selective carbonic anhydrase inhibitors and tubulin polymerization inhibitors with potent anticancer activity","volume":"303","author":"Elkotamy","year":"2025","journal-title":"Int J Biol Macromol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118784_bb0220","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/nm0997-1034","article-title":"Cell-cycle arrest versus cell death in cancer therapy","volume":"3","author":"Waldman","year":"1997","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.bmc.2026.118784_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/cells13221838","article-title":"Apoptosis: a comprehensive overview of signaling pathways, morphological changes, and physiological significance and therapeutic implications","volume":"13","author":"Mustafa","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bmc.2026.118784_bb0230","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cbin.11137","article-title":"Cell death: a review of the major forms of apoptosis, necrosis and autophagy","volume":"43","author":"D\u2019arcy","year":"2019","journal-title":"Cell Biol Int"},{"issue":"2","key":"10.1016\/j.bmc.2026.118784_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70277","article-title":"Unlocking the anticancer potential of new spirooxindoles via p53-MDM2\/MDMX dual inhibition: in vitro and in silico assessments","volume":"87","author":"El-Zoheiry","year":"2026","journal-title":"Drug Dev Res"},{"issue":"5","key":"10.1016\/j.bmc.2026.118784_bb0240","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/cac2.12416","article-title":"Tumor microenvironment signaling and therapeutics in cancer progression","volume":"43","author":"Goenka","year":"2023","journal-title":"Cancer Commun"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0245","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ophtha.2012.07.038","article-title":"Vascular endothelial growth factor a in intraocular vascular disease","volume":"120","author":"Miller","year":"2013","journal-title":"Ophthalmology"},{"issue":"5B","key":"10.1016\/j.bmc.2026.118784_bb0250","first-page":"3593","article-title":"MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer","volume":"27","author":"Quaranta","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bmc.2026.118784_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2025.1606848","article-title":"A novel thiazole-sulfonamide hybrid molecule as a promising dual tubulin\/carbonic anhydrase IX inhibitor with anticancer activity","volume":"13","author":"Khasawneh","year":"2025","journal-title":"Front Chem"},{"issue":"9","key":"10.1016\/j.bmc.2026.118784_bb0260","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.biochi.2011.05.013","article-title":"Bax: addressed to kill","volume":"93","author":"Renault","year":"2011","journal-title":"Biochimie"},{"issue":"4","key":"10.1016\/j.bmc.2026.118784_bb0265","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/bab.2233","article-title":"Caspase-3: structure, function, and biotechnological aspects","volume":"69","author":"Asadi","year":"2022","journal-title":"Biotechnol Appl Biochem"},{"issue":"509","key":"10.1016\/j.bmc.2026.118784_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0275","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc Chem Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13065-024-01130-5","article-title":"Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies","volume":"18","author":"Fouad","year":"2024","journal-title":"BMC Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118784_bb0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10822-025-00596-2","article-title":"Structure-based discovery of novel non-covalent small molecule inhibitors of USP30","volume":"39","author":"Anbazhagan","year":"2025","journal-title":"J Comput Aided Mol Des"},{"issue":"45","key":"10.1016\/j.bmc.2026.118784_bb0290","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"10.1016\/j.bmc.2026.118784_bb0295","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/acsmedchemlett.9b00276","article-title":"Structural and molecular insight into resistance mechanisms of first generation cMET inhibitors","volume":"10","author":"Collie","year":"2019","journal-title":"ACS Med Chem Lett"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:35:47Z","timestamp":1792067747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"alternative-id":["S0968089626002403"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118784","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Striking two targets with one scaffold via benzo[d]imidazole-isatin conjugates as potent dual VEGFR-2\/c-MET antagonists","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118784"}}